Go Pro
NASDAQ:PSTV

Plus Therapeutics Q1 2025 Earnings Report

Plus Therapeutics logo
$1.78 -0.09 (-4.81%)
As of 10/1/2026

Plus Therapeutics EPS Results

Actual EPS
-$14.00
Consensus EPS
-$4.25
Beat/Miss
Missed by -$9.75
One Year Ago EPS
N/A

Plus Therapeutics Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
$1.11 million
Beat/Miss
Missed by -$53.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 30, 2025
Conference Call Time
4:00PM ET

Plus Therapeutics Earnings Headlines

Plus Therapeutics’ CNSide Begins Billing as Test Volumes Surge
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.tc pixel
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics is also studying potential applications in other solid tumors.

Plus Therapeutics is headquartered in Austin, Texas, and conducts its development activities through collaborations with clinical and research institutions. The company was formerly known as Cytori Therapeutics before adopting the Plus Therapeutics name. Marc H. Hedrick serves as president and chief executive officer.

View Plus Therapeutics Profile